TNSN99170A1 - Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN99170A1 TNSN99170A1 TNTNSN99170A TNSN99170A TNSN99170A1 TN SN99170 A1 TNSN99170 A1 TN SN99170A1 TN TNSN99170 A TNTNSN99170 A TN TNSN99170A TN SN99170 A TNSN99170 A TN SN99170A TN SN99170 A1 TNSN99170 A1 TN SN99170A1
- Authority
- TN
- Tunisia
- Prior art keywords
- preparation
- pharmaceutical compositions
- tetrahydroquinolein
- derivatives
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
-L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1, R2, R3, R4, R5, R6, R7 ET R8 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES ET KITS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, POUR LE TRAITEMENT DE DIVERSES MALADIES TELLES QUE L'ATHEROSCLEROSE ET DES MALADIES CARDIO-VASCULAIRES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10092798P | 1998-09-17 | 1998-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN99170A1 true TNSN99170A1 (fr) | 2005-11-10 |
Family
ID=22282246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN99170A TNSN99170A1 (fr) | 1998-09-17 | 1999-09-13 | Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (50)
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
SE0101161D0 (sv) * | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
EP1385501A2 (fr) * | 2001-04-11 | 2004-02-04 | Atherogenics, Inc. | Procedes d'accroissement des taux de cholesterol hdl du plasma et d'amelioration de la fonctionnalite hdl avec des monoesters de probucol |
MXPA03009935A (es) | 2001-04-30 | 2004-01-29 | Pfizer Prod Inc | Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp. |
HUP0400263A2 (hu) * | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény |
EP1404300B1 (fr) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres |
PL367674A1 (en) * | 2001-06-22 | 2005-03-07 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
EP1269994A3 (fr) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament |
AU2002361811A1 (en) | 2001-12-19 | 2003-07-09 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
HUP0500165A2 (en) * | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
AU2002351748B2 (en) * | 2001-12-21 | 2009-07-09 | Novo Nordisk A/S | Amide derivatives as GK activators |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
DE60322665D1 (de) * | 2002-02-01 | 2008-09-18 | Pfizer Prod Inc | Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors |
RU2278659C9 (ru) * | 2002-02-01 | 2007-02-20 | Пфайзер Продактс Инк. | Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением |
JP2005523262A (ja) * | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
JP4881559B2 (ja) * | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | 治療薬としてのアリールカルボニル誘導体 |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7211672B2 (en) * | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
ATE327977T1 (de) * | 2002-10-21 | 2006-06-15 | Warner Lambert Co | Tetrahydrochinolin-derivate als crth2 antagonisten |
WO2004052863A1 (fr) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatoire |
US20040181075A1 (en) * | 2002-12-19 | 2004-09-16 | Weingarten M. David | Process of making chalcone derivatives |
WO2004056358A1 (fr) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Formes posologiques comprenant un inhibiteur de cetp et un inhibiteur de hmg-coa reductase |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
EP1435356A1 (fr) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Dérivés de la quinoléine en tant qu'antagonistes de CRTH2 |
WO2004072042A2 (fr) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Modulation de l'activite de recepteurs nucleaires |
WO2004082675A1 (fr) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Procede pour accroitre la biodisponibilite orale de s- [2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] -2-methylpropanethioate |
AU2004222434B2 (en) * | 2003-03-17 | 2010-06-03 | Japan Tobacco Inc. | Pharmaceutical compositions of CETP inhibitors |
CA2520405A1 (fr) * | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US7923467B2 (en) | 2003-05-30 | 2011-04-12 | Ranbaxy Laboratories, Inc. | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
ATE540671T1 (de) | 2003-08-04 | 2012-01-15 | Bend Res Inc | Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien |
JP4536061B2 (ja) | 2003-09-26 | 2010-09-01 | 日本たばこ産業株式会社 | レムナントリポ蛋白生成阻害方法 |
JP2007507481A (ja) * | 2003-09-30 | 2007-03-29 | ファイザー・プロダクツ・インク | Cetp阻害薬及びその代謝産物 |
EP2098512A1 (fr) * | 2003-10-08 | 2009-09-09 | Eli Lilly & Company | Composants et procédés de traitement de la dyslopidémie |
US7390504B2 (en) * | 2003-11-07 | 2008-06-24 | Jj Pharma, Inc. | HDL-boosting combination therapy complexes |
MXPA06007667A (es) * | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
KR101494067B1 (ko) | 2004-03-05 | 2015-02-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
PL1732933T3 (pl) | 2004-03-26 | 2008-12-31 | Lilly Co Eli | Związki do leczenia dyslipidemii |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
TWI345568B (en) * | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
WO2006009819A1 (fr) * | 2004-06-18 | 2006-01-26 | Array Biopharma Inc. | Inhibiteurs de proteines de transfert d'ester de cholesteryle |
KR100859223B1 (ko) * | 2004-06-24 | 2008-09-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
CA2570688A1 (fr) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Composes et procedes destines a traiter la dyslipidemie |
US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
JP2008510835A (ja) * | 2004-08-25 | 2008-04-10 | エッセンシャリス,インク. | カリウムatpチャンネル開放因子の製剤処方、及びその使用 |
WO2006033004A1 (fr) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Composes de quinoline en tant qu'inhibiteurs de cetp |
US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
BRPI0518300A2 (pt) * | 2004-11-23 | 2008-11-11 | Warner Lambert Co | derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia |
WO2006069162A1 (fr) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Nouveaux composes heterocycliques et leurs compositions pharmaceutiques |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
DK1848430T3 (da) | 2004-12-31 | 2017-11-06 | Dr Reddys Laboratories Ltd | Nye benzylamin-derivativer som cetp-inhibitors |
EP2548894A1 (fr) | 2005-02-03 | 2013-01-23 | Bend Research, Inc. | Compositions pharmaceutiques à éfficacité améliorée |
EP1861372A1 (fr) | 2005-02-24 | 2007-12-05 | Millennium Pharmaceuticals, Inc. | Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires |
WO2006098394A1 (fr) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides |
CN101212966B (zh) * | 2005-07-01 | 2012-03-14 | 默沙东公司 | 合成cetp抑制剂的方法 |
US7999114B2 (en) * | 2005-07-08 | 2011-08-16 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
KR20080024211A (ko) * | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
MX2008000255A (es) * | 2005-07-14 | 2008-04-02 | Novo Nordisk As | Activadores de urea glucocinasa. |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ |
JP2009514851A (ja) | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
EP2404604B1 (fr) | 2006-01-05 | 2019-02-06 | Essentialis, Inc. | Sels d'ouverture de canal ATP du potassium et leurs utilisations |
UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
GB0615670D0 (en) * | 2006-08-07 | 2006-09-13 | Syngenta Participations Ag | Chemical compounds |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
WO2008079398A1 (fr) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol |
JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
CN101220021B (zh) * | 2007-01-12 | 2010-12-08 | 上海医药工业研究院 | 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用 |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
WO2008129951A1 (fr) | 2007-04-13 | 2008-10-30 | Kowa Company, Ltd. | Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant |
CA2692160A1 (fr) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Sels d'ouvreurs de canaux potassiques sensibles a l'atp et leurs utilisations |
KR101564793B1 (ko) | 2007-11-05 | 2015-10-30 | 노파르티스 아게 | 고지질혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 cetp 억제제로서의 4-벤질아미노-1-카르복시아실-피페리딘 유도체 |
PT2229356E (pt) | 2007-12-03 | 2012-01-20 | Novartis Ag | Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
RU2010128543A (ru) | 2007-12-11 | 2012-01-20 | Сайтопатфайндер, Инк. (Jp) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
BRPI1012852A2 (pt) | 2009-05-15 | 2018-06-19 | Novartis Ag | derivados de benzoxazolona como inibidores da sintase de aldoesterona |
AU2010247414B2 (en) | 2009-05-15 | 2013-08-01 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
EP2435402B1 (fr) | 2009-05-28 | 2016-04-13 | Novartis AG | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
AR076707A1 (es) | 2009-05-28 | 2011-06-29 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina |
AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
EP2501678B1 (fr) | 2009-11-17 | 2015-09-23 | Novartis AG | Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase. |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
EP2507234B1 (fr) | 2009-11-30 | 2014-03-12 | Novartis AG | Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase |
EP2571860A1 (fr) | 2010-05-21 | 2013-03-27 | Pfizer Inc | 2-phénylbenzoylamides |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
ES2648788T3 (es) | 2011-01-26 | 2018-01-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular |
WO2012120414A2 (fr) | 2011-03-04 | 2012-09-13 | Pfizer Inc. | Peptides de type edn3 et utilisations associées |
JP5629403B2 (ja) | 2011-06-17 | 2014-11-19 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Crth2受容体モジュレータとしてのシクロアルキル縮合テトラヒドロキノリン |
TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物 |
JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物 |
WO2013046045A1 (fr) | 2011-09-27 | 2013-04-04 | Dr. Reddy's Laboratories, Ltd. | Dérivés de 5 - benzylaminométhyl - 6 - aminopyrazolo [3, 4 -b] pyridine utiles comme inhibiteurs de la cholestéryl ester -transfer protéine (cetp) dans le traitement de l'athérosclérose |
MX347400B (es) | 2012-06-29 | 2017-04-18 | Univ Nac Autónoma De México | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
PT2956464T (pt) | 2013-02-14 | 2018-07-04 | Novartis Ag | Derivados de ácido bisfenil butanóico fosfónico substituído como inibidores de nep (endopeptidase neutra |
CA2909442A1 (fr) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | Derives de n-piperidin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
SG11201600208RA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
CN112755032A (zh) | 2014-08-28 | 2021-05-07 | 狄智玛制药私人有限公司 | 包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合 |
CA2959208C (fr) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Derives de pyrimidine et utilisation comme inhibiteurs de .alpha.-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
WO2016055901A1 (fr) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Composés d'amide substitué |
KR20170103970A (ko) | 2015-01-23 | 2017-09-13 | 노파르티스 아게 | 개선된 반감기를 갖는 합성 아펠린 지방산 접합체 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CA3093025A1 (fr) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Utilisations therapeutiques d'activateurs de glucokinase en combinaison avec de l'insuline ou des analogues d'insuline |
CN113574055A (zh) | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
US5401848A (en) | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active IP Right Cessation
- 1999-09-10 EE EEP200100167A patent/EE200100167A/xx unknown
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 EP EP99940426A patent/EP1114032B1/fr not_active Expired - Lifetime
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/fr active IP Right Grant
- 1999-09-10 CA CA002344248A patent/CA2344248C/fr not_active Expired - Fee Related
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/fr active
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
-
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
-
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-03-16 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown
-
2002
- 2002-02-26 HK HK02101447.5A patent/HK1039938A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN99170A1 (fr) | Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99162A1 (fr) | Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97144A1 (fr) | Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99236A1 (fr) | Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98238A1 (fr) | Macrolides nouveaux | |
TNSN98084A1 (fr) | Derives de macrolides substitues en position c-4 | |
TNSN97145A1 (fr) | Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99126A1 (fr) | Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99106A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN99142A1 (fr) | Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation. | |
TNSN98082A1 (fr) | DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A. | |
TNSN99169A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98194A1 (fr) | Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN00028A1 (fr) | Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
TNSN00033A1 (fr) | Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant | |
TNSN97110A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98036A1 (fr) | Derives d'acide hexanoique nouveaux | |
TNSN98182A1 (fr) | Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97192A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. |